Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Strontium ranelate granules in postmenopausal osteoporosis (Phase II)
CTR20131351Phase 2Active
- Sponsor
- Furen Pharmaceutical Group
- Start
- Nov 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in postmenopausal osteoporosis comparing strontium ranelate granules with placebo (2 arms). Primary endpoint: Change rate of mean lumbar spine (L1–L4) bone mineral density at 12 months. Started Nov 2013; status: active.
02
Drugs
strontium ranelate
03
Conditions
postmenopausal osteoporosis
Beyond the preview
Go deeper on CTR20131351.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20131351.